The road to Damascus is paved with good intentions
Münze Österreich
The World Conference on Lung Cancer (WCLC) is underway in Vienna, and for those who arrived early, Friday was the hottest day of the year (37°C) so far!
Is the data at the meeting as hot as the summer weather?
Companies undertake drug development with the best of intentions, but there comes a moment in time where you have to take stock of what exactly is the data is telling you?
Did we experience an epiphany or turning point at WCLC for KRAS G12C inhibitors in lung cancer? Or is there still a way to be travelled on the road to Damascus?
In this latest post we take a look at some key data presented during the meeting and what it means for those in this space.
It’s a story we’ve been following for some time, and as always, there are nuances to be had, because it’s far from black or white…
To continue reading our latest discussion on oncology new product development plus commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
